Windtree Therapeutics Files 8-K
Ticker: WINTW · Form: 8-K · Filed: Oct 1, 2024 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | 8-K |
| Filed Date | Oct 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Windtree Therapeutics filed an 8-K on Oct 1, 2024, covering Reg FD and financials.
AI Summary
On October 1, 2024, Windtree Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. The company, formerly known as Discovery Laboratories Inc. and Ansan Pharmaceuticals Inc., is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This 8-K filing provides important updates and disclosures for investors regarding Windtree Therapeutics' regulatory compliance and financial reporting.
Risk Assessment
Risk Level: low — This filing is a routine 8-K report detailing disclosures and financial information, not indicating any immediate operational or financial distress.
Key Numbers
- 001-39290 — SEC File Number (Identifies the company's filing history with the SEC.)
- 94-3171943 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Windtree Therapeutics, Inc. (company) — Registrant
- Discovery Laboratories Inc. /DE/ (company) — Former Company Name
- Ansan Pharmaceuticals Inc (company) — Former Company Name
- Ansan Inc (company) — Former Company Name
- Delaware (jurisdiction) — State of Incorporation
- October 1, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Regulation FD disclosures and to provide financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on October 1, 2024.
What is the company's state of incorporation?
The company, Windtree Therapeutics, Inc., is incorporated in Delaware.
What are some of the former names of Windtree Therapeutics, Inc.?
Windtree Therapeutics, Inc. was formerly known as Discovery Laboratories Inc. /DE/, Ansan Pharmaceuticals Inc, and Ansan Inc.
What is the company's principal business address?
The principal executive address is 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976.
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-10-01 08:55:46
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share WINT The Nasdaq Capital Ma
Filing Documents
- wint20240930_8k.htm (8-K) — 28KB
- ex_728681.htm (EX-99.1) — 23KB
- slide01.jpg (GRAPHIC) — 40KB
- slide02.jpg (GRAPHIC) — 117KB
- slide03.jpg (GRAPHIC) — 101KB
- slide04.jpg (GRAPHIC) — 69KB
- slide05.jpg (GRAPHIC) — 58KB
- slide06.jpg (GRAPHIC) — 40KB
- slide07.jpg (GRAPHIC) — 72KB
- slide08.jpg (GRAPHIC) — 65KB
- slide09.jpg (GRAPHIC) — 70KB
- slide10.jpg (GRAPHIC) — 43KB
- slide11.jpg (GRAPHIC) — 80KB
- slide12.jpg (GRAPHIC) — 44KB
- slide13.jpg (GRAPHIC) — 47KB
- slide14.jpg (GRAPHIC) — 52KB
- slide15.jpg (GRAPHIC) — 35KB
- slide16.jpg (GRAPHIC) — 56KB
- slide17.jpg (GRAPHIC) — 36KB
- slide18.jpg (GRAPHIC) — 51KB
- slide19.jpg (GRAPHIC) — 41KB
- slide20.jpg (GRAPHIC) — 49KB
- slide21.jpg (GRAPHIC) — 30KB
- slide22.jpg (GRAPHIC) — 46KB
- slide23.jpg (GRAPHIC) — 46KB
- slide24.jpg (GRAPHIC) — 45KB
- slide25.jpg (GRAPHIC) — 30KB
- slide26.jpg (GRAPHIC) — 36KB
- slide27.jpg (GRAPHIC) — 101KB
- slide28.jpg (GRAPHIC) — 45KB
- slide29.jpg (GRAPHIC) — 62KB
- slide30.jpg (GRAPHIC) — 68KB
- slide31.jpg (GRAPHIC) — 75KB
- slide32.jpg (GRAPHIC) — 54KB
- slide33.jpg (GRAPHIC) — 71KB
- slide34.jpg (GRAPHIC) — 60KB
- slide35.jpg (GRAPHIC) — 66KB
- slide36.jpg (GRAPHIC) — 74KB
- slide37.jpg (GRAPHIC) — 53KB
- slide38.jpg (GRAPHIC) — 82KB
- 0001437749-24-030303.txt ( ) — 3232KB
- wint-20241001.xsd (EX-101.SCH) — 3KB
- wint-20241001_def.xml (EX-101.DEF) — 12KB
- wint-20241001_lab.xml (EX-101.LAB) — 15KB
- wint-20241001_pre.xml (EX-101.PRE) — 12KB
- wint20240930_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. On October 1, 2024, Windtree Therapeutics, Inc. (the "Company") updated information reflected in a slide presentation, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time. The information contained in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Document 99.1 Investor Presentation of Windtree Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: October 1, 2024 Windtree Therapeutics, Inc. By: /s/ Craig E. Fraser Name: Craig E. Fraser Title: President and Chief Executive Officer